Sernova Biotherapeutics Inc
SVA.TO
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.93M | -11.21M | -13.27M | -15.81M | -20.48M |
| Total Depreciation and Amortization | 216.30K | 246.50K | 326.50K | 310.70K | 353.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.93M | 1.97M | 833.20K | 1.05M | 1.14M |
| Change in Net Operating Assets | 1.68M | 1.27M | 1.63M | 2.93M | 4.84M |
| Cash from Operations | -5.10M | -7.73M | -10.48M | -11.52M | -14.15M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 18.00K | 18.00K | 3.50K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 0.00 | 3.68M | 6.63M |
| Cash from Investing | 18.00K | 18.00K | 3.50K | 3.68M | 6.63M |
| Total Debt Issued | 4.94M | 4.94M | 4.84M | 4.67M | -- |
| Total Debt Repaid | -70.40K | -112.90K | -148.10K | -169.80K | -168.50K |
| Issuance of Common Stock | 1.55M | 266.90K | 5.21M | 5.21M | 5.23M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 58.40K | 46.60K | -188.70K | -120.30K | 72.70K |
| Cash from Financing | 4.61M | 3.62M | 6.98M | 6.89M | 3.76M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -477.20K | -4.09M | -3.49M | -942.90K | -3.76M |